Key Highlights

  • CareCloud trades barely changed on the day and nearer the floor of a 52-week range topping out at US$4.01, an awkward place for a micro-cap that has just retired its most expensive layer of capital without issuing a share.
  • For the year, reported, revenue rose 8.7% to US$120.5m and GAAP net income increased 37.5% to US$10.8m.
  • Meeting the low end of guidance would put the shares at US$2.41 on roughly twelve times earnings, for a recurring-revenue business capitalised near US$103m.
  • The cyber incident is the immediate risk. A hacker accessed one of CareCloud's six electronic health record environments in mid-March 2026 for what the company described as around eight hours; it disclosed the event on a Form 8-K, initially saying it was unlikely to affect its financial position.

Why the market is paying attention

CareCloud trades barely changed on the day and nearer the floor of a 52-week range topping out at US$4.01, an awkward place for a micro-cap that has just retired its most expensive layer of capital without issuing a share.

On 15 May the company redeemed all 1,511,372 shares of its 8.75% Series B preferred stock at US$25.25 each plus about US$2.27 of accrued dividends, roughly US$41.6m, funded by a US$50m Citizens Bank facility closed on 13 April.

The counterweight landed on 30 July, when reporting confirmed CareCloud (NASDAQ:CCLD) had begun notifying patients about a March intrusion into one of its electronic health record environments, with state filings pointing to at least 345,000 affected individuals.

What the company does

CareCloud, known as MTBC until 2020 and based in Somerset, New Jersey, sells technology-enabled services to US healthcare providers. Its core business is revenue cycle management, the unglamorous work of coding, submitting and chasing insurance claims so a practice actually gets paid, alongside cloud health records, practice management software and analytics.

Revenue is largely recurring and often priced as a percentage of the collections it recovers, tying the top line to clients' billing volumes. Healthcare IT contributed US$27.5m of the US$31.3m of March-quarter revenue, and the company says it serves more than 45,000 providers.

The economics rest on labour arbitrage: the FY2025 annual report describes roughly 3,300 staff in Pakistan and Sri Lanka and says the model depends on them. Growth has also been assembled, with more than 20 tuck-in acquisitions since the 2014 listing, most recently Medsphere in 2025 and Empower in May 2026.

Latest financial and operating performance

For the year, reported, revenue rose 8.7% to US$120.5m and GAAP net income increased 37.5% to US$10.8m. Earnings per share of US$0.10 was the first positive full-year figure since the 2014 flotation, and adjusted EBITDA rose 14.5% to US$27.5m.

The first quarter of 2026, reported on 7 May, was more mixed. Revenue grew 13% to US$31.3m and gross margin improved to 46.1% from 44.1%, but operating income fell to US$1.0m from US$2.0m, net income eased to US$922,000 from US$1.9m, and adjusted EBITDA slipped to US$5.4m.

With preferred dividends of US$1.365m still charged, the loss attributable to common shareholders was US$443,000, or US$(0.01) a share, against adjusted EPS of US$0.05. Cash at 31 March was just US$3.35m.

Guidance for 2026, reaffirmed in April and May, is revenue of US$128m-US$132m, adjusted EBITDA of US$29m-US$31m and EPS of US$0.20-US$0.23, with roughly US$25m of free cash flow flagged at the analyst day.

The catalyst: preferred equity swapped for bank debt

The redemption is more than housekeeping. CareCloud suspended dividends on both preferred series in December 2023 and resumed them early in January 2025, then spent the first quarter of 2026 paying Series B holders a second monthly dividend to clear the arrearage.

Retiring the Series B removes roughly US$3.2m of annual preferred dividends without diluting common holders, the difference between a company earning about US$10m of net income reporting meaningful EPS or seeing most of it vanish into the preferred line.

The trade-off is that a business which ended 2025 with almost no borrowings now carries a US$40m term loan and a US$10m revolver. Management has indicated free cash flow of about US$2m a month against monthly debt service of US$1m-US$1.1m. Cash interest replaces a dividend the board could switch off.

One loose end remains. The Series A preferred was mandatorily converted into common stock in March 2025 and delisted, yet 984,530 Series A shares were still outstanding, drawing about US$2.2m of dividends a year.

The bull case

The simplest argument is arithmetic. Meeting the low end of guidance would put the shares at US$2.41 on roughly twelve times earnings, for a recurring-revenue business capitalised near US$103m.

Cash conversion is real rather than adjusted. Operating cash flow of US$28.6m on US$120.5m of revenue is a genuine strength at this scale, and it funded the Empower purchase internally.

The artificial intelligence layer is specific rather than aspirational. CareCloud says its stratusAI Desk Agent autonomously resolves approximately 75% of inbound patient calls at early adopters, alongside a Voice Audit tool flagging revenue and compliance gaps in a market it sizes above US$4bn.

The bear case and the risks

The cyber incident is the immediate risk. A hacker accessed one of CareCloud's six electronic health record environments in mid-March 2026 for what the company described as around eight hours; it disclosed the event on a Form 8-K, initially saying it was unlikely to affect its financial position. By 30 July, notifications filed with five state attorneys general covered at least 345,000 individuals, with data reported to include Social Security numbers and medical records.

Liquidity is thin against the new obligations. Cash stood at US$3.35m at 31 March, ahead of a US$40m term loan drawn weeks later; the model works if free cash flow lands near the indicated US$25m.

Organic growth is harder to see than headline growth. The 13% first-quarter increase includes Medsphere, which closed in August 2025, while non-recurring services revenue fell.

Then there is concentration and governance. Around 3,300 staff in Pakistan and Sri Lanka create exposure the company itself flags, Norman Roth was still described as interim chief financial officer in the first-quarter release, and a US$60m at-the-market equity facility sits alongside the debt.

What investors should watch next

Second-quarter results. Whether guidance survives, the first full quarter of interest expense, and whether earnings attributable to common shareholders turn positive.

Margin direction. Gross margin of 46.1% is the benchmark, and quarterly adjusted EBITDA must run well above US$5.4m to reach the US$29m-US$31m target.

Breach disclosures. The final count on the US Department of Health and Human Services breach portal, any consolidated litigation, and whether remediation costs are quantified.

Cash, debt and the residual preferred. Progress against the US$40m term loan, a recovering cash balance, any move on the remaining Series A shares, and a first revenue figure for stratusAI.

Investor takeaway

CareCloud has genuinely changed shape. A decade of preferred equity has been all but cleared, the company delivered its first positive full-year EPS since listing, and guidance implies earnings roughly doubling in 2026.

Against that, the reset carries costs. Preferred dividends the board could suspend have been replaced by bank debt it cannot, cash on hand is slim, a residual Series A line still absorbs about US$2.2m a year, and the March breach has become a large notification exercise.

The premise that a reset is taking shape holds up on the financial evidence. Whether it becomes a durable re-rating depends on execution the market has not yet seen. This article is information only and not a recommendation.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.